Start Updating the natural history of hpv and anogenital cancer

Updating the natural history of hpv and anogenital cancer

Sera were selected from 1483 women aged 10–29 years, chosen as most important for informing the design of HPV vaccination programmes in the UK.

In this respect, our results are broadly similar to seroprevalence data in other populations.

of cases of anogenital warts (von Krogh et al, 2001).

Two prophylactic vaccines against HPV (a bivalent vaccine against types 16 and 18, and a quadrivalent vaccine that also includes types 6 and 11) have been shown in clinical trials to reduce persistent HPV infection and associated disease by over 90 in up to 5 years of follow-up (Harper et al, 2004; Villa et al, 2006).

In individuals who mount a detectable humoral immune response, HPV type-specific serum antibodies are an indicator of past exposure.